Pharmaceutical Innovation for Infectious Disease Management

From Troubleshooting to Sustainable Models of Engagement

by Sonja Marjanovic, Carolina Feijao

Download Free Electronic Document

FormatFile SizeNotes
PDF file 0.3 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

In this Perspective, the authors discuss the need for more sustainable and scalable ways of incentivising pharmaceutical industry innovation in response to infectious disease threats to public health. The authors consider incentives for innovation both in the current context of the COVID-19 crisis, and in the context of preventing other emerging or re-emerging infectious disease threats from becoming crises further down the line. The paper discusses the potential for innovative financial instruments, such as subscription-based models and bond-based approaches, to act as incentives. The authors also highlight the need to tackle a range of critical success factors beyond financial considerations. This includes tackling issues related to data access and the governance of data sharing, securing appropriate clinical trials infrastructure, ensuring suitable approval processes and procurement practices, and planning for manufacturing and supply chain capacity to mitigate against unintended consequences in affordability and access. Finally, the authors observe that the pharmaceutical industry will need to engage with society in ways that extend beyond producing a pill, diagnostic test or vaccine, in order to deliver on commitments made in response to any incentive systems that are put in place.

Research conducted by

This Perspective was made possible through internal funding provided by RAND Europe.

This report is part of the RAND Corporation perspective series. RAND perspectives present informed perspective on a timely topic that address the challenges facing the public and private sectors. All RAND perspectives undergo rigorous peer review to ensure high standards for research quality and objectivity.

Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.